MCM
ANIK icon

Manchester Capital Management’s Anika Therapeutics ANIK Stock Holding History

Manchester Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,475
Closed -$60K – 556
2014
Q4 		$60K Buy
1,475
+700
+90% +$27.4K 0.01% 676
2014
Q3 		$28K Buy
+775
New +$33.5K ﹤0.01% 831

Other funds holding ANIK

BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
LCP
Lombardia Capital Partners Pasadena, California $110M AUM 13.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Boston Trust Walden
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Thompson Siegel & Walmsley
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return

Manchester Capital Management's ANIK Position: Q1 2015 in Review

Manchester Capital Management sold out of Anika Therapeutics (ANIK) in Q1 2015, closing a stake of 1,475 shares — an estimated $60K sold.

Manchester Capital Management first reported a position in ANIK in Q3 2014 and held it in 2 quarters. The position peaked at $60K in Q4 2014. 159 funds tracked by Wall St. Rank hold ANIK as of Q1 2015.

  • Manchester Capital Management reported no remaining Anika Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Manchester Capital Management sold 1,475 Anika Therapeutics shares in Q1 2015, an estimated $60K.
  • Manchester Capital Management first reported a position in Anika Therapeutics in Q3 2014 and held it in 2 quarters.
  • Manchester Capital Management's Anika Therapeutics position peaked at $60K in Q4 2014.
  • 159 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2015.

Based on Manchester Capital Management's 13F filing for Q1 2015, filed 7 May 2015.